Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Inclusion Criteria: * AML favorable or intermediate ELN risk * Achieved true 1st complete response (CR) (absolute neutrophil count \[ANC\] and platelet count \> 1,000/ul and 100,000/ul respectively) after first cycle of induction therapy, with no minimal residual disease (MRD) * No measurable residual disease (MRD) as assessed by flow cytometry after initial induction therapy * Performance score Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2 * Creatinine \< 2.0 mg/dl and calculated by Cockcroft-Gault (CG) formula or 24 hour measured creatinine clearance (CRCL) \> 50 * Not pregnant * Received 1-2 courses of post remission "consolidation" therapy prior to mobilization PBSC * No MRD by flow, cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing prior to collection of autologous PBSC collection * Plan is to collect at least 3 x 10\^6 CD34+ PBSC/kg cryopreserved; preference is 4-5 X 10\^6 CD34 cells/kg Exclusion Criteria: * Life expectancy is severely limited by diseases other than AML * Total bilirubin \> 2.0 mg/dl or serum glutamic-oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase (SGPT) \> 2.5 x upper limit of normal (ULN) * History of Gilbert's disease * Uncontrolled arrhythmias, left ventricular ejection fraction (LVEF) \< 50% or corrected diffusion capacity of the lung for carbon monoxide (DLCO) \< 50% * Significant active infection that precludes transplant * Hepatitis B or C viremia at time of ASCT * History of central nervous system (CNS) involvement with AML